Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBT: 2016-2025

Historic EBT for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $43.4 million.

  • Collegium Pharmaceutical's EBT rose 178.79% to $43.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.9 million, marking a year-over-year decrease of 36.84%. This contributed to the annual value of $98.6 million for FY2024, which is 30.15% up from last year.
  • Collegium Pharmaceutical's EBT amounted to $43.4 million in Q3 2025, which was up 155.13% from $17.0 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's EBT ranged from a high of $46.7 million in Q4 2023 and a low of -$38.9 million during Q4 2021.
  • In the last 3 years, Collegium Pharmaceutical's EBT had a median value of $17.8 million in 2023 and averaged $21.6 million.
  • The largest annual percentage gain for Collegium Pharmaceutical's EBT in the last 5 years was 3,338.67% (2021), contrasted with its biggest fall of 635.33% (2021).
  • Quarterly analysis of 5 years shows Collegium Pharmaceutical's EBT stood at -$38.9 million in 2021, then surged by 79.96% to -$7.8 million in 2022, then skyrocketed by 699.54% to $46.7 million in 2023, then tumbled by 63.03% to $17.3 million in 2024, then skyrocketed by 178.79% to $43.4 million in 2025.
  • Its EBT was $43.4 million in Q3 2025, compared to $17.0 million in Q2 2025 and $3.1 million in Q1 2025.